Characteristics for all participants: stratified by UPCR goal and eGFR slope at −2.0 mL/min/1.73 m2/year
| Variable | Met UPCR goal (18) | Above UPCR goal (6) | |
|---|---|---|---|
| eGFR slope strata (mL/min/1.73 m2/year): N | (≥−2.0): 6 | (<−2.0): 12 | (<−2.0): 6 |
| Age at visit 0 (year) | 40.6 (30.9–51.8) | 46.6 (42.9–51.3) | 41.5 (35.1–51.7) |
| Age: ERT started (years) | 37.9 (30.3–46.1) | 45.1 (40.4–49.2) | 37.2 (33.5–47.2) |
| Interval: ERT start to visit 0 (years) | 5.1 (0.4–5.5) | 2.6 (0.3–4.1) | 3.6 (1.4–4.1) |
| Initial follow-up (visit 0) | |||
| Systolic blood pressure (mm Hg) | 101 (98–107) | 112 (109–126) | 111 (100–120) |
| Serum K+ (mEq/L) | 4.2 (3.7–5.0) | 4.2 (4.0–4.6) | 4.2 (3.9–5.2) |
| UPCR (g/g) | 0.1 (0.1–0.3) | 0.3 (0.2–0.9) | 0.9 (0.7–1.7) |
| ACR (mg/g) | 61 (5.7–96) | 162 (69–598) | 627 (456–1126) |
| eGFR (mL/min/1.73 m2) | 88 (56–116) | 62 (48–78) | 61 (45–81) |
| Average of follow-up visits | |||
| Systolic blood pressure (mm Hg) | 104 (102–111) | 119 (107–130) | 112 (107–117) |
| Serum K+ (mEq/L) | 4.8 (4.0–5.6) | 4.9 (4.7–5.2) | 4.9 (4.0–5.5) |
| UPCR (g/g) | 0.3 (0.1–0.5) | 0.4 (0.3–0.7) | 0.9 (0.7–1.5) |
| ACR (mg/g) | 122 (18–234) | 254 (123–491) | 579 (454–733) |
| eGFR (mL/min/1.73 m2) | 80 (75–126) | 56 (45–75) | 68 (45–73) |
| Last follow-up visit | |||
| Systolic blood pressure (mm Hg) | 110 (101–118) | 120 (113–140) | 111 (101–120) |
| Serum K+ (mEq/L) | 4.1 (3.9–4.9) | 4.5 (4.0–4.7) | 4.6 (3.8–4.8) |
| UPCR (g/g) | 0.3 (0.1–0.7) | 0.3 (0.2–1.0) | 1.0 (0.8–1.7) |
| ACR (mg/g) | 67 (8.4–481) | 198 (73–962) | 719 (533–1196) |
| eGFR (mL/min/1.73 m2) | 97 (75–121) | 62 (51–85) | 47 (35–90) |
| Medication score | 1.5 (1–2) | 3 (2–3) | 3 (3–3) |
| eGFR slope (mL/min/1.73 m2/year) | −0.1 (−1.1 to 1.3) | −4.2 (−5.3 to −3.6) | −7.0 (−9.0 to −5.6) |
| eGFR intercept (mL/min/1.73 m2) | 90 (70–124) | 63 (50–80) | 56 (45–82) |
Continuous variables presented as median (25th–75th centile). Medication score defined as: 0, none; 1, ACE inhibitor or ARB; 2, ACE inhibitor plus ARB, or diuretic; 3, ACE inhibitor or ARB at maximum dose.
p<0.05 for differences in medians, comparing groups to reference (met UPCR goal and slope −2.0 mL/min.1.73 m2/year); with two-sample Wilcoxon rank-sum test (shown in bold).
UPCR goal defined as UPCR at first treatment visit ≤0.5 g/g, or averaged treatment UPCR ≤ 50% of baseline UPCR (visit–3), or averaged treatment UPCR <0.5 g/g. ARB, angiotensin type 1 receptor blocker; ACR, albumin to creatinine ratio; eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; UPCR, urinary protein to creatinine ratio (g/g).